0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Observation |

Telaprevir-Induced Acquired Perforating Dermatosis FREE

Charlotte Pernet, MD1,2,3; Georges-Philippe Pageaux, MD, PhD1,2,4; Bernard Guillot, MD, PhD1,2,5; Olivier Dereure, MD, PhD1,2,5; Didier Bessis, MD1,2,5
[+] Author Affiliations
1Department of Dermatology, St Eloi Hospital, Montpellier, France
2University of Montpellier I, Montpellier, France
3Department of Pathology, Gui de Chauliac Hospital, Montpellier, France
4Liver Transplant Unit, St Eloi Hospital, Montpellier, France
5INSERM (Institut national de la santé et de la recherche médicale) U1058, Montpellier, France
JAMA Dermatol. 2014;150(12):1371-1372. doi:10.1001/jamadermatol.2014.1171.
Text Size: A A A
Published online

Since its approval in 2011, a novel serine protease inhibitor, telaprevir, has been increasingly used in combination with pegylated interferon and ribavirin as an effective treatment for chronic hepatitis C virus (HCV) infection. However, it was found to cause cutaneous eruption, mostly pruritic eczematous dermatitis, in 56% of patients as opposed to 34% of patients taking peginterferon and ribavirin alone.1 Moreover, severe adverse cutaneous events were reported to be more frequent in telaprevir-treated patients (3.7% vs 0.4%).1 We report herein the first case to our knowledge of acquired perforating dermatosis (APD) induced by telaprevir in a patient with HCV infection.

REPORT OF A CASE

A man in his 50s with HCV infection was referred for pruritic ulcerated papules on the lower legs. The lesions appeared 3 weeks after the patient started treatment with telaprevir (2250 mg/d orally) (Janssen-Cilag) in combination with ribavirin (1200 mg/d orally) (Hoffman-LaRoche) and pegylated interferon alfa-2a (180 μg/wk subcutaneously) (Hoffman-LaRoche). He had previously been treated with peginterferon and ribavirin without cutaneous adverse effects. Blood test results for human immunodeficiency virus (HIV) were negative. Serum α-fetoprotein level was normal, and abdominal computed tomography did not show evidence of hepatocellular carcinoma. He had no diabetes mellitus or chronic kidney failure and was taking no other medication.

Physical examination revealed extensive xerosis and ulcerated papular and nodular lesions on the lower legs, each with an inflammatory border and a central keratotic plug (Figure 1). Histologic examination of a lesion specimen revealed a focal epidermal ulceration covered by a hyperkeratotic crust containing necrotic debris and inflammatory cells. Collagen bundles and elastic fibers oriented perpendicularly to the surface were extruded through the epidermis (Figure 2). A diagnosis of APD was rendered. Telaprevir therapy was discontinued, and the patient was treated with 1 application per day of betamethasone dipropionate and petroleum jelly (Vaseline; Unilever), with slow but progressive improvement observed within 2 weeks and no new lesions. All lesions entirely resolved within 2 months, leaving pigmented and atrophic scars.

Place holder to copy figure label and caption
Figure 1.
Telaprevir-Induced Acquired Perforating Dermatosis on the Lower Legs

Ulcerated papules of the lower legs, each with inflammatory border and central keratotic plug.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Histopathologic Features

Histologic examination revealed a cup-shaped depression in the epidermis covered by a hyperkeratotic crust containing necrotic debris, inflammatory cells, and collagen bundles oriented perpendicularly to the surface and extruded through the epidermis (hematoxylin-eosin, original magnification ×40).

Graphic Jump Location

DISCUSSION

In our observation, APD was quite likely secondary to telaprevir treatment, given the delayed onset of lesions, the improvement after treatment discontinuation, and the prior benign treatment course with pegylated interferon alfa-2a and ribavirin.

Acquired perforating dermatosis has been associated with several diseases, including diabetes mellitus, chronic renal failure, malignant conditions and AIDS. Rare observations of APD associated with HCV infection have been reported, but in all cases, the eruption was related to either renal failure or hepatocellular carcinoma.2,3 Drug-induced APD is exceptional and has mostly been described for new biologics like natalizumab, gefitinib, infliximab, etanercept, bevacizumab, erlotinib, and sorafenib.4 Although telaprevir-induced APD has never been described, 2 cases of APD induced by indinavir, another protease inhibitor, were described in patients with HIV in the absence of diabetes mellitus or chronic kidney failure.5

The etiopathogenic mechanisms involved in APD are uncertain. However, it is widely believed that in susceptible individuals, APD is a cutaneous response to superficial trauma caused by scratching. Hypoxia, accumulation of fibronectin, and increased levels of matrix-degrading metalloproteins may also contribute to the transepidermal elimination of dermal collagen.4 We suggest that in susceptible individuals, APD is a potential severe cutaneous adverse effect of telaprevir brought on by the itching and repeated scratching often caused by this protease inhibitor.

ARTICLE INFORMATION

Corresponding Author: Charlotte Pernet, MD, Department of Dermatology, St Eloi Hospital, 80 Avenue A, Fliche, 34295 Montpellier CEDEX 5, France (c-pernet@chu-montpellier.fr).

Published Online: September 24, 2014. doi:10.1001/jamadermatol.2014.1171.

Conflict of Interest Disclosures: None reported.

REFERENCES

Roujeau  JC, Mockenhaupt  M, Tahan  SR,  et al.  Telaprevir-related dermatitis. JAMA Dermatol. 2013;149(2):152-158.
PubMed   |  Link to Article
Saray  Y, Seçkin  D, Bilezikçi  B.  Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol. 2006;20(6):679-688.
PubMed   |  Link to Article
Kiliç  A, Gönül  M, Cakmak  SK, Gül  U, Demiriz  M.  Acquired reactive perforating collagenosis as a presenting sign of hepatocellular carcinoma. Eur J Dermatol. 2006;16(4):447.
PubMed
Piqué-Duran  E, Eguía  P, García-Vázquez  O.  Acquired perforating dermatosis associated with natalizumab. J Am Acad Dermatol. 2013;68(6):e185-e187.
PubMed   |  Link to Article
Calista  D, Morri  M.  Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. Eur J Dermatol. 2008;18(1):84-85.
PubMed

Figures

Place holder to copy figure label and caption
Figure 1.
Telaprevir-Induced Acquired Perforating Dermatosis on the Lower Legs

Ulcerated papules of the lower legs, each with inflammatory border and central keratotic plug.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Histopathologic Features

Histologic examination revealed a cup-shaped depression in the epidermis covered by a hyperkeratotic crust containing necrotic debris, inflammatory cells, and collagen bundles oriented perpendicularly to the surface and extruded through the epidermis (hematoxylin-eosin, original magnification ×40).

Graphic Jump Location

Tables

References

Roujeau  JC, Mockenhaupt  M, Tahan  SR,  et al.  Telaprevir-related dermatitis. JAMA Dermatol. 2013;149(2):152-158.
PubMed   |  Link to Article
Saray  Y, Seçkin  D, Bilezikçi  B.  Acquired perforating dermatosis: clinicopathological features in twenty-two cases. J Eur Acad Dermatol Venereol. 2006;20(6):679-688.
PubMed   |  Link to Article
Kiliç  A, Gönül  M, Cakmak  SK, Gül  U, Demiriz  M.  Acquired reactive perforating collagenosis as a presenting sign of hepatocellular carcinoma. Eur J Dermatol. 2006;16(4):447.
PubMed
Piqué-Duran  E, Eguía  P, García-Vázquez  O.  Acquired perforating dermatosis associated with natalizumab. J Am Acad Dermatol. 2013;68(6):e185-e187.
PubMed   |  Link to Article
Calista  D, Morri  M.  Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. Eur J Dermatol. 2008;18(1):84-85.
PubMed

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

653 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
CME Related by Topic
Jobs